Schwab Charles Investment Management Inc. increased its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 409,519 shares of the biotechnology company’s stock after purchasing an additional 17,727 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.54% of Momenta Pharmaceuticals worth $5,713,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also added to or reduced their stakes in MNTA. Public Employees Retirement System of Ohio purchased a new position in Momenta Pharmaceuticals during the 2nd quarter valued at about $247,000. Sicart Associates LLC purchased a new position in Momenta Pharmaceuticals during the 4th quarter valued at about $279,000. Crossmark Global Holdings Inc. purchased a new position in Momenta Pharmaceuticals during the 3rd quarter valued at about $319,000. Municipal Employees Retirement System of Michigan grew its stake in Momenta Pharmaceuticals by 81.8% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 28,690 shares of the biotechnology company’s stock valued at $531,000 after acquiring an additional 12,910 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in Momenta Pharmaceuticals by 82.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 39,492 shares of the biotechnology company’s stock valued at $731,000 after acquiring an additional 17,852 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Stifel Nicolaus reiterated a “hold” rating and set a $18.00 price target on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. BidaskClub lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Finally, ValuEngine upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. Momenta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $15.33.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The firm had revenue of $64.60 million during the quarter, compared to analyst estimates of $66.59 million. During the same period in the previous year, the company earned $0.60 EPS. The company’s revenue for the quarter was up 88.9% on a year-over-year basis. equities research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 EPS for the current year.
In other news, CEO Craig A. Wheeler sold 3,938 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $16.46, for a total transaction of $64,819.48. Following the sale, the chief executive officer now directly owns 239,869 shares in the company, valued at $3,948,243.74. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Craig A. Wheeler sold 35,666 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total value of $503,247.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,502 shares of company stock valued at $1,661,696. Corporate insiders own 4.40% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.